Medicine
Northera 200 mg capsule
Northera 200 mg capsule is a prescription medicine containing Droxidopa for oral use, marketed by Lundbeck Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
NORTHERA capsules should be stored at 20°C to 25°C (68°F to 77°F), excursions…
Key facts
- Active ingredient (INN)
- Droxidopa
- Brand
- Northera
- Strength
- 200 mg
- Dosage form
- Capsule
- Route
- Oral
- Packs
- 90 capsules
- Marketing authorisation holder
- Lundbeck Pharmaceuticals
- Manufacturer
- Lundbeck Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- NORTHERA capsules should be stored at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C01CA27 Droxidopa
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 September 2014
- Identifiers
- RxCUI 1490026, 1490032, 1490034 +3DailyMed set ID 2179f02c-48d7-48eb-8007-5ae43d8d16bcNDC 67386-821Application NDA203202
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 90 capsule in 1 bottle | 67386-821-19 | Lundbeck Pharmaceuticals | 1 September 2014 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 18 February 2014 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Droxidopa 200 mg capsule.
Other strengths and forms of Droxidopa
Clinical summary
Droxidopa is a prescription medicine indicated for the treatment of orthostatic dizziness, among other approved uses. It is available as capsules for oral use. MedsAcross supplies Droxidopa for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DroxidopaFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Northera prescribing information (Lundbeck Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Northera 200 mg capsule for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.